Trimethoprim-Sulfamethoxazole for the Prevention of Methicillin-Resistant Staphylococcus aureus Pneumonia in Severely Burned Patients
| Autor: | Toshibumi Otsuka, Akio Kimura, Toru Mochizuki, Kenji Nishizawa, Kunihiro Mashiko, Yasuhiro Yamamoto |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male Adolescent Administration Oral Microbial Sensitivity Tests urologic and male genital diseases medicine.disease_cause Placebo Anti-Infective Agents Pneumonia Staphylococcal Trimethoprim Sulfamethoxazole Drug Combination Humans Medicine Prospective Studies Child Prospective cohort study Aged Aged 80 and over Cross Infection business.industry Incidence Sulfamethoxazole Incidence (epidemiology) Respiratory disease Middle Aged bacterial infections and mycoses medicine.disease Respiration Artificial Methicillin-resistant Staphylococcus aureus Trimethoprim female genital diseases and pregnancy complications Pneumonia Anesthesia Female Methicillin Resistance Drug Monitoring Burns business medicine.drug |
| Zdroj: | The Journal of Trauma: Injury, Infection, and Critical Care. 45:383-387 |
| ISSN: | 1079-6061 |
| DOI: | 10.1097/00005373-199808000-00032 |
| Popis: | Background: Patients with severe burns are at increased risk of developing methicillin-resistant Staphylococcus aureus (MRSA) ventilator-associated pneumonia. This study was designed to determine whether MRSA pneumonia can be prevented by prophylactic administration of trimethoprim-sulfamethoxazole (TMP-SMX). Methods: We conducted a prospective, randomized, placebo-controlled study in patients with severe burns (≥20%), who required ventilator support. Prophylaxis was done with oral TMP-SMX (80 mg/400 mg) three times daily for 10 days from 4 to 6 days after burn injury. The incidence of MRSA pneumonia and the side effects were evaluated during the administration period. Results: Twenty-one patients were assigned to receive TMP-SMX, and 19 patients to receive placebo. The incidence of MRSA pneumonia was 4.8% in the TMP-SMX group and 36.8% in the placebo group, showing a significant difference (p = 0.017). No major side effects of therapy were seen in the TMP-SMX group. Conclusion: Prophylactic treatment with TMP-SMX can prevent MRSA pneumonia in severely burned patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|